Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach-Reference-Cited by-同舟云学术

Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach

Published:2024-01-05 Issue:1 Volume:17 Page:26-29
ISSN:1865-5041
Container-title:memo - Magazine of European Medical Oncology
language:en
Short-container-title:memo

Author:

Schmitz Katja

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12254-023-00950-w.pdf

Reference19 articles.

1. access: 05.05.2023.. https://clinicaltrials.gov/..

2. Athauda, A., et al. Claudin 18.2‑a FAST-moving target in gastric cancer?. Annals of oncology: official journal of the European Society for Medical Oncology (2021) 32(5), 584–586. https://doi.org/10.1016/j.annonc.2021.02.021

3. Cao W, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10(1):38. https://doi.org/10.1186/s40364-022-00385-1.

4. Shitara, K., et al. Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). J Clin Oncol 41, 2023 (suppl 16; abstr 4035); https://doi.org/10.1200/JCO.2023.41.16_suppl.4035

5. Shitara, K., et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2‑positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet (2023).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. OeGHO annual meeting 2023—best of oncology;memo - Magazine of European Medical Oncology;2024-02